5.0712
price up icon4.02%   0.1962
 
loading

Immunitybio Inc Aktie (IBRX) Neueste Nachrichten

pulisher
10:18 AM

ImmunityBio, nCartes announce collaboration on clinical trial data fulfillment - TipRanks

10:18 AM
pulisher
10:06 AM

ImmunityBio partners with nCartes to streamline trials By Investing.com - Investing.com UK

10:06 AM
pulisher
10:00 AM

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - PR Newswire

10:00 AM
pulisher
Nov 20, 2024

Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria

Nov 20, 2024
pulisher
Nov 20, 2024

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace

Nov 19, 2024
pulisher
Nov 19, 2024

ImmunityBio announces new data from QUILT 3.032 study - TipRanks

Nov 19, 2024
pulisher
Nov 14, 2024

Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St

Nov 14, 2024
pulisher
Nov 13, 2024

ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

ImmunityBio: Q3 Earnings Snapshot - The Pioneer

Nov 12, 2024
pulisher
Nov 12, 2024

ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 12, 2024

Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations

Nov 12, 2024
pulisher
Nov 12, 2024

ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

ImmunityBio Reports Third-Quarter 2024 Financial Results - The Bakersfield Californian

Nov 12, 2024
pulisher
Nov 08, 2024

(IBRX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 04, 2024

ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3%Should You Sell? - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Why ImmunityBio Stock Is Trading Higher Thursday - MSN

Nov 04, 2024
pulisher
Oct 31, 2024

Commit To Buy ImmunityBio At $4, Earn 25% Using Options - Nasdaq

Oct 31, 2024
pulisher
Oct 30, 2024

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

LA Times Owner Faces Investor Suit Over Drug Co.'s Woes - Law360

Oct 30, 2024
pulisher
Oct 30, 2024

Penny Stock Trades: Joby Aviation and ImmunityBio - Baystreet.ca

Oct 30, 2024
pulisher
Oct 29, 2024

ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

ImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6%Here's Why - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

(IBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 29, 2024
pulisher
Oct 29, 2024

ImmunityBio (IBRX) Stock Soaring on Plans to Bridge Gaps in Cancer Treatments - TipRanks

Oct 29, 2024
pulisher
Oct 28, 2024

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025 - Seeking Alpha

Oct 28, 2024
pulisher
Oct 27, 2024

Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? - Benzinga

Oct 27, 2024
pulisher
Oct 27, 2024

ImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume – Still a Buy? - Defense World

Oct 27, 2024
pulisher
Oct 25, 2024

ImmunityBio Stock Heats Up, Catches Retail's Eye On Cancer Drug Trial Progress And Analyst’s Bullish Call - Barchart

Oct 25, 2024
pulisher
Oct 25, 2024

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful - Seeking Alpha

Oct 25, 2024
pulisher
Oct 25, 2024

ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

ImmunityBio stock jumps after trial update (IBRX:NASDAQ) - Seeking Alpha

Oct 25, 2024
pulisher
Oct 25, 2024

Stock Traders Buy High Volume of ImmunityBio Call Options (NASDAQ:IBRX) - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

EF Hutton sees over 600% upside in biotech small cap ImmunityBio - Kursiv Media

Oct 25, 2024
pulisher
Oct 25, 2024

Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga

Oct 25, 2024
pulisher
Oct 25, 2024

ImmunityBio (IBRX) Stock Extends Pre-Hour Rally Following Clinical Trial News - Stocks Telegraph

Oct 25, 2024
pulisher
Oct 25, 2024

ImmunityBio commences CD19 t-haNK cell therapy trial for NHL - Yahoo! Voices

Oct 25, 2024
pulisher
Oct 25, 2024

ImmunityBio begins dosing in Phase 1 trial of CAR-NK therapy for relapsed NHL - World Pharmaceutical Frontiers

Oct 25, 2024
pulisher
Oct 25, 2024

ImmunityBio (NASDAQ:IBRX) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I - Defense World

Oct 25, 2024
pulisher
Oct 24, 2024

ImmunityBio (NASDAQ:IBRX) Trading 7.8% HigherHere's What Happened - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

ImmunityBio Stock Could Rocket 800%, Analyst Says - Barron's

Oct 24, 2024
pulisher
Oct 24, 2024

This Biotech Stock Could Rocket 800%, Analyst Says - MSN

Oct 24, 2024
pulisher
Oct 24, 2024

ImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHL - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma - Business Wire

Oct 24, 2024
pulisher
Oct 24, 2024

ImmunityBio (NASDAQ:IBRX) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

800% Upside For This Biotech StockAnalyst Initiates Coverage On Bladder Cancer Focused ImmunityBio - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's What Happened - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

EF Hutton sets stock target with buy rating for ImmunityBio, cites cancer therapy - Investing.com

Oct 23, 2024
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):